A Randomized, Multicenter, Double-Masked, Vehicle-Controlled, Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Trial Profile

A Randomized, Multicenter, Double-Masked, Vehicle-Controlled, Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Completed
Phase of Trial: Phase II/III

Latest Information Update: 23 Nov 2016

At a glance

  • Drugs Ciclosporin (Primary)
  • Indications Keratoconjunctivitis sicca
  • Focus Therapeutic Use
  • Sponsors Ocular Technologies
  • Most Recent Events

    • 13 Nov 2015 Status changed from active, no longer recruiting to completed, according to an Auven Therapeutics media release.
    • 13 Nov 2015 Results published in an Auven Therapeutics media release.
    • 13 Nov 2015 Primary endpoint 'Conjunctival staining' has been met, according to an Auven Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top